Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Influx HealthtechNSE:INFLUX -0.65%32 Altman Z-Score is 19.98 as of Jul. 13, 2026, which is 42% above its 10-year median of 14.09. GuruFocus rates NSE:INFLUX with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 953 Drug Manufacturers companies, Influx Healthtech ranks better than 94.96% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 19.98 is strong.
Influx Healthtech has a Altman Z-Score of 19.98, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Influx Healthtech's Altman Z-Score or its related term are showing as below:
NSE:INFLUX'
s Altman Z-Score Range Over the Past 10 Years
Min: 14.09 Med: 14.09 Max: 19.98
Current: 19.98
During the past 5 years, Influx Healthtech's highest Altman Z-Score was 19.98. The lowest was 14.09. And the median was 14.09.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Influx Healthtech Altman Z-Score Related Terms
Influx Healthtech Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Influx Healthtech's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INFLUX vs ZTS, UTHR: Altman Z-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Influx Healthtech's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Influx Healthtech Altman Z-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Influx Healthtech's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Influx Healthtech's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Influx Healthtech's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.4749
+
1.4
*
0
+
3.3
*
0.2216
+
0.6
*
29.1576
+
1.0
*
1.187
=
19.98
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Influx Healthtech (NSE:INFLUX) has a Altman Z-Score of 19.98 as of Jul. 13, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Influx Healthtech and its competitors. This is 42% above median its historical median of 14.09. Over the past decade, Influx Healthtech's Altman Z-Score has ranged from 14.09 to 19.98. According to the industry distribution chart, Influx Healthtech ranks #48 out of 953 companies in the Drug Manufacturers industry, placing it in the top 5%.
Is Influx Healthtech's Altman Z-Score too high?
Influx Healthtech's current Altman Z-Score of 19.98 is 42% above median its 10-year median of 14.09. Over the past 10 years, this metric has ranged from a low of 14.09 to a high of 19.98. The Drug Manufacturers industry median Altman Z-Score is 3.25. Influx Healthtech's value of 19.98 is 514.8% above this industry median. Based on the distribution chart, Influx Healthtech ranks #48 out of 953 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Influx Healthtech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Influx Healthtech's Altman Z-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Influx Healthtech ranks #48 out of 953 companies for Altman Z-Score. This places Influx Healthtech in the top 5% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 3.25. Influx Healthtech's value of 19.98 is 514.8% above this benchmark. Historically, Influx Healthtech's own Altman Z-Score has ranged from 14.09 to 19.98 over the past decade. While the company's 10-year median is 14.09 vs. the industry median of 3.25, Influx Healthtech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Drug Manufacturers company?
The median Altman Z-Score among Drug Manufacturers companies is 3.25, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Influx Healthtech's current Altman Z-Score of 19.98 is 514.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Influx Healthtech and its competitors. For the Drug Manufacturers industry, the median Altman Z-Score is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Influx Healthtech's current Altman Z-Score is 19.98, which is 42% above median its own 10-year median of 14.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Influx Healthtech stock overvalued right now?
Influx Healthtech (NSE:INFLUX) has a current Altman Z-Score of 19.98. The current Altman Z-Score is 19.98, which is 42% above median its 10-year median of 14.09 and 514.8% above the Drug Manufacturers industry median of 3.25. Influx Healthtech's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Influx Healthtech (NSE:INFLUX), the current Altman Z-Score is 19.98 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Influx Healthtech Ltd is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates manufacturing facilities located in Thane. Its expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables. The company generates the majority of its revenue from sale of products.
32GF Score
Get the complete analysis for NSE:INFLUX
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFLUX has been successfully added to your 
